#China #Shanghai #biotech #Henlius #Serplulimab

Henlius Reports Impressive Growth in 2025

Henlius, a Shanghai-based biopharmaceutical company, has announced its annual financial results for 2025. This year marks an impressive third consecutive year of profitability for the firm since it first achieved this milestone in 2023. The company's strong performance is underscored by significant growth in both revenue and profits, underlining its commitment to innovation and global expansion.

During the reporting period, Henlius recorded a total revenue of RMB 6.6666 billion, reflecting a robust year-on-year increase of 16.5%. Additionally, it reported a net profit of RMB 0.8270 billion, a testament to its effective operational strategies and market positioning. The firm invested significantly into research and development, with total RD expenditure reaching RMB 2.4919 billion, marking a remarkable growth of 35.4%.

With rising profits from its research and development initiatives, pre-RD profits recorded a healthy growth of 26.2%, climbing to RMB 2.3425 billion. This trend highlights Henlius’ continuous investment in innovation, ensuring a sustainable and resilient profitability model coupled with high-quality growth.

Global Expansion and Product Performance

In 2025, Henlius placed a substantial focus on enhancing its global presence, achieving product revenue of RMB 5.7746 billion. A significant driver of this growth has been its core products, including serplulimab (known as Hetronifly® in Europe) and HANQUYOU (trastuzumab, marketed as HERCESSI™ in the U.S. and Zercepac® in Europe). The company’s international sales increased notably, with revenue outside of China exceeding RMB 200 million, doubling Year-on-Year. This surge showcases Henlius’ strategic partnerships and its ability to navigate global market dynamics effectively.

Serplulimab, Henlius’ flagship product, has been a standout performer. The product alone generated global sales of RMB 1.4926 billion, reflecting an impressive growth rate of 13.7% compared to previous periods. Additionally, Henlius made notable achievements in the breast cancer drug market, with revenue totaling RMB 3.2675 billion. This success can be attributed to the company’s ability to cater to a diverse patient demographic, thus generating stable cash flow from its matured products.

Henlius expanded its offerings in key markets by commercially launching two dosage strengths of HLX14 (denosumab) in the U.S. and several European countries, yielding sales of RMB 9.8 million during the year. The company continues to ramp up its innovation pipeline, with key drugs like dulpatatug (HLX22, a novel anti-HER2 mAb) and HLX43 (PD-L1 ADC) progressing through critical clinical trial phases.

Focus on Quality and Future Goals

As Henlius continues on its path of growth, its integrated capabilities spanning RD, clinical operations, regulatory affairs, manufacturing, and commercialization serve as a competitive edge. The company is accelerating its transition into a China-rooted global biopharma model, which aims at delivering high-quality biologics globally.

Looking ahead, Henlius remains committed to expanding its product offerings and enhancing patient access to its biological treatments. With a robust strategy for growth and a focus on innovation, Henlius is set to make a significant impact in the global biopharmaceutical arena. As the company approaches the future, its dedication to quality and patient outcomes will continue to be at the forefront of its mission.